Singapore's Tikva Allocell targets solid cancer barrier with US$8M Series A funding, aiming to make a significant impact in solid tumours, which account for the majority of cancer cases worldwide.
Singapore's Tikva Allocell targets solid cancer barrier with US$8M Series A funding, aiming to make a significant impact in solid tumours, which account for the majority of cancer cases worldwide.
Source: e27 Asia
StartupSingaporeCancerCell Therapy
